Test Details: Mutations in the EGFR gene correlate with clinical responsiveness to the TK inhibitor. In majority of patients with highly responsive tumors, the tumor contains somatic mutation of the EGFR gene. Screening for the mutation in the lung cancer helps to stratify patient responsiveness to Gefitinib and Erlotinib.